

Sunday, July 13, 2025

Room A (Kairaku 1+2)		
Time	Title	Faculty
7:00-7:30	Registration	
7:30-8:20	Breakfast Symposium 2 Criteria regarding surgical treatment in Japan and future treatment strategies for advanced HCC <i>Sponsored by Eisai Co., Ltd.</i>	Chair: Norihiro Kokudo (Tokyo) Speakers: Junichi Shindoh (Tokyo), Shohei Komatsu (Kobe)
Session 5a. Systemic Therapy for Early-stage HCC		Chairs: Ming Kuang (Guangzhou), Qiang Gao (Shanghai) Commentators: Akinobu Taketomi (Sapporo), Makoto Ueno (Tokyo)
8:30-8:45	Adjuvant Therapy after Loco-regional Treatment in Hepatocellular Carcinoma	Pierce Chow (Singapore)
8:45-9:00	Evolving Landscape and Evidence for Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma	Wei Zhang (Wuhan)
9:00-9:15	Treatment Strategy for Borderline Resectable Hepatocellular Carcinoma	Tomoaki Yoh (Kyoto)
9:15-9:30	Perioperative treatment of Liver Transplant	Kyung-Suk Suh (Seoul)
9:30-9:45	The Potential Role of Systemic Therapy in Early-Stage Hepatocellular Carcinoma: A Special Clinical Consideration	Kaoru Tsuchiya (Tokyo)
9:45-10:00	Discussion	
10:00-10:15	Coffee Break & Poster Viewing	
State of the Art Lecture 4.		Chair: Masatoshi Kudo (Osaka)
10:15-10:45	Current status and Future perspectives of multidisciplinary treatment for advanced HCC in Kobe University	Takumi Fukumoto (Kobe)
Session 6a. Systemic Therapy for Intermediate-stage HCC		Chairs: Joong Won Park (Goyang), Ming Shi (Guangzhou) Commentators: Takamichi Murakami (Kobe), Teiji Kuzuya (Nagoya)
10:45-11:00	TACE refractoriness and TACE unsuitability	Do Young Kim (Seoul)
11:00-11:15	Is systemic therapy alone feasible for intermediate-stage HCC?	Yi-Hsiang Huang (Taipei)
11:15-11:30	Combination therapy of TACE with Systemic therapy	Masatoshi Kudo (Osaka)
11:30-11:45	Utilizing the conversion concept based on disease status following systemic chemotherapy for hepatocellular carcinoma	Shohei Komatsu (Kobe)
11:45-12:00	Optimizing Immunotherapy: Radiologist's Perspective	Eisuke Ueshima (Kobe)
12:00-12:15	Discussion	

AGENDA

Sunday, July 13, 2025

Room A (Kairaku 1+2)		
Time	Title	Faculty
12:15-13:05	Luncheon Symposium 3 The Trend of Systemic Therapy and Multidisciplinary Treatment for Hepatocellular Carcinoma <i>Sponsored by CHUGAI PHARMACEUTICAL CO.,LTD.</i>	Chair: Masafumi Ikeda (Chiba) Speakers: Takanori Ito (Nagoya), Sadahisa Ogasawara (Chiba)
Session 7a. Systemic Therapy for Advanced-stage HCC		Chairs: Kwang-Hyub Han (Seoul), Sheng-Long Ye (Shanghai) Commentators: Atsushi Hiraoka (Matsuyama), Toshifumi Tada (Kobe)
13:15-13:30	First-Line Therapy	Thomas Yau (Hong Kong)
13:30-13:45	Second-line therapy for unresectable hepatocellular carcinoma (HCC)	Chiun Hsu (Taipei)
13:45-14:00	Evolving strategies for late-line treatment in advanced hepatocellular carcinoma	Sadahisa Ogasawara (Chiba)
14:00-14:15	Locoregional Treatment in Advanced HCC: Moving Toward a New Necessity	Hyunchul Rhim (Changwon)
14:15-14:30	Trends in Drug Development for HCC	Ann-Lii Cheng (Taipei)
14:30-14:45	Discussion	
State of the Art Lecture 5.		Chair: Ann-Lii Cheng (Taipei)
14:45-15:15	Navigating the optimal management of HCC	Kwang-Hyub Han (Seoul)
15:15-15:30	Coffee Break & Poster Viewing	
Session 8a. Presentations of Selected Abstracts I		Chairs: Jian Zhou (Shanghai), Masayuki Kurosaki (Tokyo) Commentators: Takahiro Kodama (Osaka), Kenji Fukushima (Kobe)
15:30-15:40	Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab	Masaki Omori (Kobe)
15:40-15:50	The usefulness of the non-invasive scoring systems for the hepatocarcinogenesis in patients with MASLD/MASH	Takashi Nishimura (Hyogo)
15:50-16:00	Tumor Budding Predicts Poor Survival in Hepatocellular Carcinoma Patients Treated with Neoadjuvant/Conversion Therapy: A Cohort Study Using ITBCC Criteria	Pu-Wen Shen (Shanghai)
16:00-16:20	Discussion	
16:20-16:30	Awards ceremony	
Closing Ceremony		Chairs: Takumi Fukumoto, Michiie Sakamoto, Masafumi Ikeda
16:30-16:40	Summary of APPLE 2025 & Introduction of APPLE 2026	Jian Zhou (Shanghai)

Room B (Kairaku 3)		
Time	Title	Faculty
Session 5b. Debate session		Chairs: Tan To Cheung (Hong Kong), Yi-Hsiang Huang (Taipei) Commentators: Kazuomi Ueshima (Osaka), Shinji Itoh (Fukuoka)
8:30-8:40	Case 1. Treatment strategy combining ICI chemotherapy and surgery for advanced hepatocellular carcinoma	Masaki Kaibori (Osaka)
8:40-8:50	Case 1. Borderline resectable HCC: Neoadjuvant therapy	Etsuro Hatano (Kyoto)
8:50-9:00	Case 2. Conversion possible: resection	Junichi Shindoh (Tokyo)
9:00-9:10	Case 2. Conversion possible: Continue systemic therapy	Satoshi Kobayashi (Yokohama)
9:10-9:20	Case 3. Some up-to-7 out hepatocellular carcinomas can be cured by transarterial chemoembolization alone	Shiro Miyayama (Fukui)
9:20-9:30	Case 3. Intermediate HCC: TACE+Systemic therapy	Stephen Chan (Hong Kong)
9:30-9:40	Case 4. Advanced stage HCC with Vp4: Systemic therapy	Yutaka Yasui (Tokyo)
9:40-9:50	Case 4. Advanced stage HCC with Vp4: FOLFOX-HAIC	Min-Ke He (Guangzhou)
9:50-10:00	Discussion	
10:00-10:15	Coffee Break & Poster Viewing	
Session 6b. Hepatology in HCC Management		Chairs: Andrew Zhu (Shanghai), Ryosuke Tateishi (Tokyo) Commentators: Masato Ozaka (Tokyo), Tomokazu Kawaoka (Hiroshima)
10:45-11:00	Clinical Feasibility of Circulating Tumor DNA in Advanced Hepatocellular Carcinoma	Hong Jae Chon (Seongnam)
11:00-11:15	Novel Biomarkers on Immunotherapy Treatment for Unresectable HCC	Takahiro Kodama (Osaka)
11:15-11:30	Gut-liver axis-mediated mechanism of liver cancer development: gut microbial components alter liver tumor microenvironment	Naoko Ohtani (Osaka)
11:30-11:45	Factors Influencing Immune Checkpoint Inhibitor Efficacy	Taro Shibuki (Kashiwa)
11:45-12:00	Disparities between viral versus metabolic HCC	Ming-Lung Yu (Kaohsiung)
12:00-12:15	Discussion	
12:15-13:05	Luncheon Symposium 4 A New Era in Systemic Therapy for Hepatocellular Carcinoma: Therapeutic Innovation with the Opdivo-Yervoy Combination Sponsored by Bristol-Myers Squibb/ ONO PHARMACEUTICAL CO., LTD.	Chair: Masayuki Kurosaki (Tokyo) Speaker: Masatoshi Kudo (Osaka)

AGENDA

Sunday, July 13, 2025

Room B (Kairaku 3)		
Time	Title	Faculty
Session 7b. Novel strategies for CCA: Others		Chairs: Do-Youn Oh (Seoul), Masafumi Ikeda (Kashiwa) Commentators: Hiroshi Imaoka (Kashiwa), Masashi Kanai (Kyoto)
13:15-13:30	Transplantation for Advanced IHC	William R. Jarnagin (New York)
13:30-13:45	Noval Targets of Cholangiocarcinoma	Ying-Chun Shen (Taipei)
13:45-14:00	Molecular Heterogeneity in CCA and predictive biomarkers	Su Pin Choo (Singapore)
14:00-14:15	Immune Landscape of Intrahepatic Cholangiocarcinoma and its Clinical Implication	Naoshi Nishida (Osaka)
14:15-14:30	Optimal Dose of Immune Checkpoint Inhibitor – Flat-, Body-weight based-, or Low-dose?	Li-Tzong Chen (Tainan)
14:30-14:45	Discussion	
State of the Art Lecture 6.		Chair: Chiun Hsu (Taiwan)
14:45-15:15	Towards Multi-Omics Spatial Analysis to Reveal Cancer Heterogeneity	Yutaka Suzuki (Kashiwa)
15:15-15:30	Coffee Break & Poster Viewing	
Session 8b. Presentations of Selected Abstracts II		Chairs: Ming-Lung Yu (Kaohsiung), Makoto Ueno (Tokyo) Commentators: Masato Ozaka (Tokyo), Satoshi Shimizu (Saitama)
15:30-15:40	Dose-Response Association Between Body Mass Index and the Risk of Cholangiocarcinoma	Joo-Hyun Park (Korea)
15:40-15:50	Survival Outcomes of Transarterial Treatment versus Systemic Therapy as Initial Treatment for Hepatocellular Carcinoma with Extrahepatic Metastasis	Jaejun Lee (Korea)
15:50-16:00	Reconstructing Exosomal Biomechanical Signatures from RNA Profiles to Predict Hepatocellular Carcinoma Progression: A Deep Learning-Based Approach	Rifaldy Fajar (Indonesia)
16:00-16:20	Discussion	
(Awards ceremony, move to Room A)		